The company is outgrowing its own explanations: management keeps telling investors the reported numbers are not the busi
The model's full reasoning — Q3 2018 call → NOWe need to determine if management conveys that the reported results do not represent the business as it is actually running today — that is, the reported period is stale relative to the operating present. Look for management's own words indicating a gap between the reported numbers and current business activity, grounded in concrete things already happening. Key points from the call: - Bob Bradway: "we're in the midst of a period of high volatility... our fundamental objectives... remain intact." He mentions new products with double-digit unit volume growth, but that's about the quarter. - David Meline: financial results, guidance raised. Nothing about the reported period being stale. - Murdo Gordon: discusses product performance, launches, etc. He mentions Aimovig launch, biosimilars launched, etc. But does he say the reported numbers don't reflect current business? He says "we're excited to have launched our first commercial biosimilar products in Europe" — that's recent, but not necessarily that the quarter's numbers are stale. He also mentions Repatha price cut, but that's forward-looking. - David Reese: pipeline updates, new programs entering clinic. That's about future, not about the reported period being stale. The question is specifically about whether management conveys that the reported results do not represent the business they are actually running today. That is, the reported period is behind the current state. Look for language like "the quarter doesn't reflect our current momentum" or "we've already moved beyond these numbers" etc. In the call, there is no explicit statement that the reported results are stale. They discuss strong performance, but they don't say "the quarter's numbers are not indicative of our current run rate" or anything like that. They do mention that some things happened after the quarter (like biosimilar launches, Aimovig launch, etc.) but that's normal for any earnings call. The guidance is raised, but that's about future expectations, not about the reported period being unrepresentative. The instruction says: "Answer YES when management's own words convey... ONE coherent posture: the printed period is stale relative to the operating present." Here, management does not seem to convey that. They are presenting results and outlook, but not saying the results are behind the current business.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| KOPN | Kopin Corporation | Q4 2023 | 2024-03-14 | C+ |
| PFE | Pfizer Inc. | Q4 2023 | 2024-01-30 | F |
| SCPH | scPharmaceuticals Inc. | Q3 2023 | 2023-11-08 | B |
| NBTX | Nanobiotix S.A. | Q2 2023 | 2023-09-27 | D |
| PRPH | ProPhase Labs, Inc. | Q1 2023 | 2023-05-11 | F |
| VRE | Veris Residential, Inc. | Q4 2022 | 2023-02-22 | D |
| SOL | ReneSola Ltd | Q3 2022 | 2022-12-01 | C+ |
| FLL | Full House Resorts, Inc. | Q3 2022 | 2022-11-07 | B |
| OPK | OPKO Health, Inc. | Q1 2022 | 2022-05-09 | D |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
| PRIM | Primoris Services Corporation | Q2 2018 | 2018-08-11 | C+ |
| LIND | Lindblad Expeditions Holdings, Inc. | Q2 2017 | 2017-08-06 | C |
VRE · Q4 2022 → YESThe question is: Does management convey that the reported results for the period do not represent the business the company is actually running today? That the just-reported numbers describe a company ...YES The transcript shows management repeatedly framing the reported period as transitional and not reflective of the current business: the shift to a pure-play multi-family company has already reduced office and hotel exposure while driving multi-family NOI share to 98%, with Haus25 leased at 95% ahead of schedule and same-store NOI guidance of 4-6% for 2023. They explicitly note that earnings variability stems from the ongoing asset sales and reallocation, with the business now positioned for growth as the transformation concludes, and they highlight post-period activity like additional sales and stabilized properties to underscore that the reported numbers capture a pre-transition state.
PFE · Q4 2023 → YESThe question is: Does management convey that the reported results do not represent the business the company is actually running today? That the just-reported numbers describe a company that has alread...NO The transcript shows management framing 2023 results as a challenging year with declines driven by COVID products, while positioning 2024 as a year of execution and growth through new priorities like the Seagen acquisition (closed late in 2023 with minimal contribution) and new product launches. This is a standard results-and 2024 outlook discussion, with forward-looking elements on pipeline, margins, and capital allocation rather than indicating the reported period is stale relative to current operations.
PRIM · Q2 2018 → YESThe question is whether management conveys that the reported results for Q2 2018 do not represent the business the company is actually running today. Specifically, if the printed period is stale relat...YES The transcript shows management repeatedly framing the Q2 results as a partial picture due to the late June 1 acquisition of Willbros. They note the business is "running as planned," highlight one-month revenue contribution of $1.